This Week in Psychiatry — Jul 27, 2026

Welcome to This Week in Psychiatry. This week we're covering 6 notable papers spanning reproductive and neuromodulatory psychiatry, global and substance use interventions, and precision neurosteroid biomarker development. Let's dive in.

Beginning with reproductive and neuromodulatory interventions, two studies examine distinct clinical populations and modalities. In a population-based Danish registry cohort study published in JAMA Psychiatry, Steinberg and colleagues investigated whether medication or procedural first-trimester abortions are associated with subsequent psychotropic medication use among females aged 12 to 38 years [1]. Analyzing data from over 67,000 individuals, the authors found that in fully adjusted models using conventional p-values, there were small increased risks of any first psychotropic medication redemption in the first year after both medication abortion and procedural abortion [1]. However, when applying a Bonferroni-corrected p-value threshold, these small increased risks in the first year no longer met criteria for statistical significance [1]. Notably, decreases in the risk of psychotropic medication redemption were observed more than 5 years after both abortion methods [1]. Shifting to neuromodulation in mood disorders, Xu and colleagues published a randomized, double-blind, sham-controlled trial in Molecular Psychiatry evaluating adjunctive transcranial alternating current stimulation in 60 participants with bipolar depression [2]. Patients receiving active twice-daily 10-Hz transcranial alternating current stimulation over two weeks alongside lithium showed significantly higher antidepressant response rates at week 2, at 46.7% compared to 20% in the sham group, and at week 4, at 70% compared to 43.3% [2]. Active stimulation also showed greater reductions in anxiety and sleep symptoms and fewer manic symptoms, with a generally safe and well-tolerated profile, though the authors emphasize these findings remain hypothesis-generating pending confirmation in larger studies [2].

Turning next to substance use disorders, three papers evaluate innovative delivery models and novel pharmacotherapeutic targets. In Global Health, Greene and colleagues conducted a hybrid, type 1 randomized controlled trial in the Mantapala refugee settlement in Zambia, evaluating screening, brief intervention, and referral to treatment compared to treatment as usual for alcohol use among 400 Congolese refugees and host community members [3]. Alcohol use identification test scores reduced significantly more in the screening, brief intervention, and referral to treatment group at 6 months and 12 months, with an incremental cost per improvement of 158 United States dollars, demonstrating that task-shifted delivery of brief interventions is both feasible and effective in humanitarian settings [3]. Expanding on addiction pharmacotherapy, two reviews in Biological Psychiatry explore the rapidly evolving role of incretin-based therapies. Klausen and Fink-Jensen provided a narrative review of clinical evidence for glucagon-like peptide-1 receptor agonists in alcohol use disorder, synthesizing data from three randomized trials showing reductions in alcohol cue reactivity and consumption, alongside consistent registry and real-world findings [4]. Complementing this, Grigson and colleagues reviewed preclinical and human data on glucagon-like peptide-1 receptor agonists and dual or triple agonists as candidate treatments for opioid use disorder [5]. While preclinical models show reduced opioid taking and seeking, human data thus far includes a small clinical trial showing a 40% reduction in opioid craving with liraglutide, and large database analyses showing a 40% reduction in opioid overdose and hospital admissions among patients treated for diabetes or obesity [5].

Finally, addressing the challenge of biological heterogeneity in psychiatric illness, Dargan, Walton, and Maguire published a review in Biological Psychiatry examining the potential of neurosteroids for precision medicine [6]. The authors discuss how neurosteroid-based treatments have proven effective for postpartum depression but failed in major depressive disorder, likely due to an inability to properly stratify patient populations [6]. Emerging studies suggest that measuring endogenous neurosteroidogenesis capacity could serve as a transdiagnostic biomarker to identify individuals at risk for conditions like postpartum depression and predict treatment response to neurosteroid-based therapies [6].

If you only have time for one paper this week, make it the trial by Xu and colleagues in Molecular Psychiatry on transcranial alternating current stimulation for bipolar depression [2]. It provides rigorous, randomized controlled data demonstrating early clinical improvement in depressive, anxiety, and sleep symptoms with an adjunctive device-based intervention that addresses the severe therapeutic limitations of pharmacotherapy alone in bipolar depression [2].

Here are the key takeaways from this week in Psychiatry. First, first-trimester abortion methods do not confer a sustained elevation in psychotropic medication use when evaluated with strict statistical correction [1]. Second, adjunctive transcranial alternating current stimulation offers a promising, well-tolerated early intervention for depressive and anxiety symptoms in bipolar depression [2]. Third, task-shifted screening, brief intervention, and referral to treatment successfully reduces alcohol use in low-resource humanitarian settings [3]. Fourth, incretin-based therapies show consistent signal across preclinical, registry, and early clinical studies for reducing craving and consumption in both alcohol and opioid use disorders [4, 5]. Fifth, measuring endogenous neurosteroidogenesis capacity holds strong potential as a biomarker to guide precision medicine and predict treatment response in mood disorders [6].

That's your roundup for This Week in Psychiatry. The full transcript and references are available on the episode page in your AudioScholar library. This is an AI-curated summary — for clinical decisions, always consult primary sources and current guidelines. See you next week.

If this weekly briefing is useful, follow the show in your podcast app so new episodes arrive automatically. And for audio briefings on your own clinical questions and papers, visit audioscholar dot C C.

This is an automated summary generated by artificial intelligence, which can make mistakes. Always review the original source materials.